pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Tezspire
drug · antibody
save

tezepelumab

Marketedupdated 6mo ago
by $AMGN AMGEN INC🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval16 co-mentions · 4 sources
  • drugTEZSPIRE16 co-mentions · 4 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.

indications

investigational
Asthma

targets

Thymic stromal lymphopoietin

all catalysts(4)

approval · 4
Dec 17, 2021
approval
$AZN178.84-1.88%
5y ago
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Feb 1, 2023
approval
$AZN178.84-1.88%
4y ago
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
May 26, 2023
approval
$AZN178.84-1.88%
3y ago
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Oct 17, 2025
approval
$AZN178.84-1.88%
1y ago
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→

Trials studying tezepelumab

  • phase3A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthmarecruitingn=231
  • phase3Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumabrecruitingn=400
  • phase3Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitisactive not recruitingn=368
  • phase3A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumabactive not recruitingn=181
  • phase3Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.active not recruitingn=310
  • —Tezspire Cardiac Events PASSrecruitingn=16,640
  • —Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italyactive not recruitingn=315
  • phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)recruitingn=990

News(10)

  • Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
    A phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.
    fiercebiotech · 2d ago
  • Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
    Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.
    fiercebiotech · 5d ago
  • Windward prices $175M IPO to advance China-licensed lung drugs
    The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
    biopharma_dive · 5d ago
  • Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
    Windward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.
    fiercebiotech · 9d ago
  • Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 win
    Alcon acquires Neurotech: The Swiss eye specialist paid $550 million upfront to acquire Neurotech Pharmaceuticals and could make additional payments if certain milestones are met. Alcon gains hold…
    endpoints · 28d ago
  • Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
    Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
    biopharma_dive · 1mo ago
  • AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
    With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…
    fiercebiotech · 2mo ago
  • AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
    Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
    biospace · 2mo ago
  • New data could widen use of AstraZeneca, Amgen immune disease drug
    Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
    biopharma_dive · 2mo ago
  • AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
    AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…
    biospace · 2mo ago
view all news mentions →
brand
Tezspire
trade names
Tezspire
generic
tezepelumab-ekko
MOA
Thymic stromal lymphopoietin inhibitor
indication
Eosinophilic Esophagitis
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?